Abstract Search

ea0089c19 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Transformation of G1-G2 Neuroendocrine Tumors (NETs) to Neuroendocrine Carcinomas (NECs) Following Peptide Receptor Radionuclide Therapy (PRRT): a Case Series

Cordero-Hernandez Igryl S. , Ross Alicia C. , Dasari Arvind , Halperin Daniel M. , Chasen Beth , Yao James C.

Background: We observed patients with well-differentiated NETs who received PRRT with 177Lu-dotatate and later developed rapid disease progression with biopsy-proven histologic transformation to NECs, an outcome that has not been previously described. In this series, we characterize the clinicopathologic features and outcomes of patients whose tumors underwent poorly-differentiated transformation.Methods: After obtaining IRB approval, we condu...

2 shares

ea0099oc7.2 | Oral Communications 7: Endocrine-related Cancer | ECE2024

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

Ferone Diego , Halperin Daniel , Myrehaug Sten , Herrmann Ken , Pavel Marianne , Kunz Pamela , Chasen Beth , Capdevila Jaume , Tafuto Salvatore , Oh Do-Youn , Yoo Changhoon , Falk Stephen , Halfdanarson Thorvardur R , Folitar Ilya , Zhang Yufen , Santoro Paola , Aimone Paola , de Herder Wouter W , Singh Simron

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...

0 shares

Endocrine Abstracts

Transformation of G1-G2 Neuroendocrine Tumors (NETs) to Neuroendocrine Carcinomas (NECs) Following Peptide Receptor Radionuclide Therapy (PRRT): a Case Series

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

BiosciAbstracts